Gene therapy wins the inside track at EMA; PPD files for IPO
→ Gene therapy maker Orchard Therapeutics has been granted an accelerated assessment for OTL-200 by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The gene therapy — in development in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy — being used towards the treatment of metachromatic leukodystrophy.
→ Pharmaceutical Product Development has announced that its parent company, PPD, Inc has submitted a draft to the SEC relating to the proposal of an IPO of the parent company’s common stock. Number of shares and price range have not yet been determined.
→ Boston-based Biofourmis has inked a collaboration with Novartis to work on a project for managing patients with heart failure (HF) beginning in Southeast Asia, with potential plans to expand globally. The companies say that the goal is to improve clinical outcomes by using Biofourmis’ lead product BiovitalsHF to identify early signs of HF exacerbations to enable early interventions in patients with HF with reduced ejection fraction.
→ China’s 3SBio — which earlier this year licensed rights to three immuno-oncology assets discovered by Verseau Therapeutics — along with their partners at Verseau have announced the selection of monoclonal antibody VTX-0811, targeting PSGL-1, as their first licensed program under their partnership focused on the development and commercialization of monoclonal antibodies in the field of immuno-oncology for a broad range of cancers.